Halozyme Therapeutics, Inc.
HALOHalozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
Drugs in Pipeline
10
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
HALOZYME Reports Financial Results
Filed: 2026-01-28 AccNo: 0001159036-26-000011 Size: 262 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
SourceHylenex
Pain
Gemcitabine
Stage IV Pancreatic Cancer
Insulin aspart
Diabetes Mellitus, Type II
Mitomycin C
Bladder Cancer
Humalog
Type 1 Diabetes Mellitus
PEGPH20
Metastatic Pancreatic Cancer
rHuPH20
Dermatitis, Allergic Contact
regular human insulin
Diabetes Mellitus, Type 1
Humulin-R
Diabetes Mellitus, Type 2
Insulin lispro
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Hylenex | Phase 3 | Pain | - | - |
Gemcitabine | Phase 2 | Stage IV Pancreatic Cancer | - | - |
Insulin aspart | Phase 2 | Diabetes Mellitus, Type II | - | - |
Mitomycin C | Phase 2 | Bladder Cancer | - | - |
Humalog | Phase 2 | Type 1 Diabetes Mellitus | - | - |
PEGPH20 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
rHuPH20 | Phase 2 | Dermatitis, Allergic Contact | - | - |
regular human insulin | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Humulin-R | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Insulin lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Halozyme Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Halozyme Therapeutics, Inc.'s (HALO) pipeline across Phase 3, Phase 2. Its lead program is Hylenex (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Halozyme Therapeutics, Inc.'s next FDA catalyst?→
Halozyme Therapeutics, Inc.'s (HALO) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HALO biotech catalysts?→
Add HALO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Halozyme Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.